| Literature DB >> 30155805 |
Yudong Liu1, Peng Zhang1, Yabing Zheng2, Chunlin Yang1, Tong Du1, Mengru Ge1, Xiaotian Chang2, Ruisheng Duan1, Guozhao Ma3.
Abstract
Alzheimer's disease (AD) is a well-known neurodegenerative disease. Deposition of β-amyloid protein (Aβ) oligomers plays a crucial role in the disease progression. Previous studies showed that toxicity induced by Aβ oligomers in cultured neurons and adult rat brain was partially mediated by activation of glutamatergic N-methyl-D-aspartate receptors (NMDAR). Additionally, memantine, a noncompetitive NMDAR antagonist, can significantly improve cognitive functions in some AD patients. However, little is currently known about the potential role of NMDAR antagonist on the regulation of P-MARCKS protein to Aβ1-42 oligomers induced neurotoxicity. The protective effect and mechanism of NMDAR antagonist on primary neurons exposed to Aβ1-42 oligomers were investigated in the study. We have defined that the Aβ1-42 treatment decreased cell viability and increased apoptosis. Moreover, Aβ1-42 oligomers exposure increased P-MARCKS and PIP2 expressions, while decreased SYP expression. However, NMDAR antagonist pretreatment ameliorates Aβ1-42 oligomers induced neuronal apoptosis and partially reverses the expression of P-MARCKS, PIP2 and SYP. In conclusion, NMDAR antagonist may ameliorate neurotoxicity induced by Aβ1-42 oligomers through reducing neuronal apoptosis and protecting synaptic plasticity in rat primary neurons. The mechanism involved may be mediated by the variation of protein P-MARCKS.Entities:
Keywords: Alzheimer’s disease; Aβ1−42 oligomers; Cell apoptosis; P-MARCKS; Synaptic plasticity
Mesh:
Substances:
Year: 2018 PMID: 30155805 DOI: 10.1007/s11064-018-2622-8
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996